Nuwellis, Inc. Reports Board and Officer Changes
Ticker: NUWE · Form: 8-K · Filed: Oct 8, 2025 · CIK: 1506492
| Field | Detail |
|---|---|
| Company | Nuwellis, Inc. (NUWE) |
| Form Type | 8-K |
| Filed Date | Oct 8, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
TL;DR
Nuwellis board shakeup and comp changes effective Oct 7.
AI Summary
Nuwellis, Inc. filed an 8-K on October 8, 2025, reporting changes related to its board of directors and executive compensation. The filing indicates a departure of directors or certain officers, the election of new directors, and updates to compensatory arrangements for certain officers, effective October 7, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directorship and officer roles, especially without further detail in this initial report, can introduce uncertainty about leadership stability and strategic direction.
Key Players & Entities
- Nuwellis, Inc. (company) — Registrant
- October 7, 2025 (date) — Effective date of reported changes
- October 8, 2025 (date) — Filing date of the 8-K
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but the specific names and details of any departures or new appointments are not provided in this summary.
Were there any departures of officers mentioned in the filing?
The filing mentions 'Departure of Directors or Certain Officers' as an item, suggesting potential officer changes, but specific details are not elaborated here.
What is the nature of the updates to compensatory arrangements?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item, indicating changes to compensation, but the specifics of these arrangements are not detailed in this summary.
What is the effective date of the reported events?
The earliest event reported is dated October 7, 2025.
What is the primary business of Nuwellis, Inc.?
Nuwellis, Inc. is in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry, SIC code 3845.
Filing Stats: 1,103 words · 4 min read · ~4 pages · Grade level 10.9 · Accepted 2025-10-08 17:10:35
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share NUWE Nasdaq Capital Marke
Filing Documents
- ef20056785_8k.htm (8-K) — 31KB
- 0001140361-25-037713.txt ( ) — 156KB
- nuwe-20251007.xsd (EX-101.SCH) — 4KB
- nuwe-20251007_lab.xml (EX-101.LAB) — 21KB
- nuwe-20251007_pre.xml (EX-101.PRE) — 16KB
- ef20056785_8k_htm.xml (XML) — 4KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Financial Officer On October 7, 2025, Robert B. Scott notified Nuwellis, Inc., a Delaware corporation (the " Company ") of his decision to resign as the Chief Financial Officer of the Company. Mr. Scott's last date with the Company is expected to be on or about October 24, 2025 (the " Separation Date "). Mr. Scott's resignation is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or procedures. The Company expects to commence a formal search process for the position of Chief Financial Officer for the Company. Appointment of Interim Chief Financial Officer On October 8, 2025, the Board of Directors of the Company (the " Board ") appointed John L. Erb, the Company's President and Chief Executive Officer, beginning on the Separation Date, as the interim Chief Financial Officer, the interim Principal Financial Officer, and interim Principal Accounting Officer. Mr. Erb, age 76, has served as the Company's President and Chief Executive Officer since June 2025. Mr. Erb has served as a director of the Company since September 2012, as chairman of our Board since October 2012 and as Interim President and Chief Executive Officer since February 2025, before entering the role of President and Chief Executive Officer in June 2025. Previously, Mr. Erb served as president and chief executive officer from November 2015 to January 2021. He was executive chairman of the board (during 2007) and chief executive officer (from 2001 to 2006) of the previous owner of the Aquadex system, which was then known as CHF Solutions, Inc., a medical device company involved in the development, manufacturing and distribution of devices to treat congestive heart failure. Mr. Erb previously served as chief executive officer (from 2007 to 2020) of NuAx, Inc. (
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 8, 2025 NUWELLIS, INC. By: /s/ John L. Erb Name: John L. Erb Title: President and Chief Executive Officer